EP1056445B1 - Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent - Google Patents
Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent Download PDFInfo
- Publication number
- EP1056445B1 EP1056445B1 EP99913165A EP99913165A EP1056445B1 EP 1056445 B1 EP1056445 B1 EP 1056445B1 EP 99913165 A EP99913165 A EP 99913165A EP 99913165 A EP99913165 A EP 99913165A EP 1056445 B1 EP1056445 B1 EP 1056445B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- absorption
- promoting agent
- active ingredient
- formulation according
- release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 0 C*c1ccccc1*(C)(C)C Chemical compound C*c1ccccc1*(C)(C)C 0.000 description 2
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0007—Effervescent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Definitions
- the invention relates to orally administrable galenic forms comprising one or more active ingredients which are hydrophilic or ionizable in physiological media in combination with one or more excipients.
- These galenic forms are preferably solid forms such as tablets or gelatin capsules.
- the galenic compositions of the invention are particularly advantageous in that they allow improved absorption of active ingredients which are hydrophilic and/or ionizable in physiological media, by the transmembrane or paracellular route, because of their particular excipient composition.
- control of the absorption of the active ingredients at the level of the gastrointestinal tract will ensure the efficacy of the therapy used.
- modulation of the release makes it possible to ensure better therapeutic cover and to improve tolerance and compliance.
- the galenic forms of the invention allow improvement in the absorption of the active ingredients which are hydrophilic and/or ionizable in physiological media, the control of the kinetics of release and the maintenance of the yield of absorption, this being also in the case of solid pharmaceutical forms such as tablets, gelatin capsules or microgranules.
- galenic forms of the invention are particularly appropriate for the administration of active substances which are hydrophilic and/or ionizable in physiological media, they are also suitable for the administration of lipophilic substances.
- the pharmaceutical dosage forms of the invention ensure excellent reproducibility of the results, while allowing increased control of the rate of release during the phase of prolonged release of the active ingredient.
- the tablets of the invention are moreover advantageous from the point of view of the formulation of the active ingredients since a judicious choice of the excipients leads to tablets with high concentrations of active ingredients.
- the invention provides more precisely orally administrable galenic forms comprising an active ingredient which is hydrophilic and/or ionizable in physiological media, an absorption-promoting agent having an HLB (hydrophilic/lipophilic balance value) greater than 8 and one or more pharmaceutically acceptable excipients.
- an absorption-promoting agent having an HLB (hydrophilic/lipophilic balance value) greater than 8 and one or more pharmaceutically acceptable excipients.
- the absorption-promoting agent consists of one or more lipid substances chosen from:
- lipid substances are of natural or synthetic origin, or alternatively are obtained by semisynthesis. A good number of them are commercially available or are easily prepared from commercial products.
- the polysorbates are esters of fatty acids of polyethoxylated sorbitan.
- Polyethoxylated sorbitan offers polyethoxylated sorbitol and polyethoxylated sorbitol anhydrides.
- the expression "polysorbate” designates both mono- and polyesters of fatty acids.
- the polysorbates used according to the invention are mono-, di- or triesters of saturated or unsaturated fatty acids, in which the fatty acids are preferably C 8 -C 22 , better still C 12 -C 18 . There may be mentioned more particularly monolaurate, monopalmitate, mono- and tristearate, monooleate and monoisostearate.
- the polysorbates used are the product of the esterification of fatty acids with the copolymer of a molecule of sorbitol or of one of its anhydrides and of 3 to 30 molecules of ethylene oxide.
- polysorbates will be used whose molecular weight varies between 450 and 2000, better still between 500 and 1900.
- Such polysorbates are commercially available, especially under the trade name Tween® .
- the ethers of polyoxyethylene and alkyl have the general formula: CH 3 (CH 2 ) x (OCH 2 CH 2 ) y OH in which x is an integer between 8 and 22, preferably between 12 and 18, and y is an integer from 10 to 60.
- x is an integer between 8 and 22, preferably between 12 and 18, and y is an integer from 10 to 60.
- monocetyl ether of polyethylene glycol monolauryl ether of polyethylene glycol, monooleyl ether of polyethylene glycol and monostearyl ether of polyethylene glycol. These compounds are commercially available, especially under the trade name Brij® .
- esters of polyoxyethylene and fatty acids are either fatty acid monoesters of the formula: RCO-(OCH 2 CH 2 ) n -OH where R represents the residue of a fatty acid and n the degree of polymerization of the polyethoxylated chain, or fatty acid diesters of formula: RCO-(OCH 2 CH 2 ) n -OCOR where R and n are as defined above, or mixtures of these monoesters and of these diesters.
- RCO-(OCH 2 CH 2 ) n -OH where R represents the residue of a fatty acid and n the degree of polymerization of the polyethoxylated chain
- fatty acid diesters of formula: RCO-(OCH 2 CH 2 ) n -OCOR where R and n are as defined above, or mixtures of these monoesters and of these diesters.
- the polyethylene glycols used as starting material have variable average molecular masses of between 100 and 7000, preferably between 150 and 6000.
- the starting fatty acids are saturated or unsaturated and generally have from 8 to 22 carbon atoms, better still from 12 to 18 carbon atoms.
- the esters of polyoxyethylene and fatty acid are especially marketed by the company AKZO-NOBEL.
- the fatty alcohols which can be used according to the invention are saturated or unsaturated, and have preferably from 8 to 22 carbon atoms, better still from 12 to 18 carbon atoms.
- the fatty acids are saturated or unsaturated, and have preferably from 8 to 22 carbon atoms, or better still from 12 to 18 carbon atoms.
- the bile acids are well known to persons skilled in the art. There may be mentioned glycocholic acid and taurodeoxycholic acid as preferred bile acids.
- the promoting agent may comprise a bile acid salt obtained by reacting this acid with a pharmaceutically acceptable base.
- the salts of alkali and alkaline-earth metals are particularly advantageous, such as sodium glycocholate.
- esters of C 1 -C 6 alkanol with fatty acids can also be used as absorption-promoting agent.
- the fatty acids leading to these esters are as defined above.
- the polyol esters are obtained by condensation of one or more fatty acids, as defined above, with a polyol comprising 2 to 6 hydroxyl functional groups.
- these esters those obtained by esterification of glycols, polyglycerols, sorbitol or its anhydrides are particularly preferred.
- glycol propylene glycol may be mentioned.
- esters of sorbitol or of its anhydrides with one or more fatty acids are fatty acid esters of sorbitan, especially marketed under the trade mark Span® .
- the polyglycolysed glycerides are mixtures of glycerides of fatty acids and of esters of polyoxyethylene with fatty acids. In these mixtures, the fatty acids are saturated or unsaturated C 8 -C 22 , for example C 8 -C 12 or C 16 -C 20 .
- the glycerides are mono-, bi- or triglycerides or mixtures thereof in any proportions.
- Polyglycolysed glycerides are marketed especially by the company Gattefosse under the trade names Labrafil® , Labrasol and Gelucire® .
- the absorption-promoting agent has an HLB greater than 8.
- the HLB is greater than 10; better still it varies between 12 and 16. It should be understood that when the absorption-promoting agent consists of a mixture of several lipid substances, it is the mixture of these substances which should have an HLB greater than 8.
- the preferred galenic forms of the invention are those for which the absorption-promoting agent comprises at least one polyglycolised glyceride, especially at least one polyglycolysed glyceride having an HLB of between 12 and 16.
- the absorption-promoting agent comprises, in combination with one or more polyglycolysed glycerides, an ester of sorbitan with one or more fatty acids.
- the absorption-promoting agent consists of a mixture of one or more polyglycolysed glycerides and a sorbitan ester with a C 8 -C 22 fatty acid, preferably a C 16 -C 20 fatty acid also having an HLB of between 12 and 16.
- sorbitan monolaurate sorbitan trilaurate
- sorbitan monoisostearate sorbitan monopalmitate
- sorbitan monostearate sorbitan sesqui-isostearate
- sorbitan sesqui-oleate sorbitan trioleate
- sorbitan tristearate sorbitan tristearate
- the lipid substances constituting the absorption-promoting agent may also play the role of lubricant, of wetting agent, of thickening agent or of plasticizer.
- glyceryl monostearate and glyceryl palmitostearate have a good lubricating power.
- Glyceryl monooleate and the fatty acid esters of polyethoxylated sorbitan play the role of wetting agent and the C 16 -C 20 fatty alcohols and fatty acids (stearic acid, cetyl alcohol), glycerol palmitostearate and more generally some fatty acid glycerides among the monoglycerides, diglycerides and triglycerides are also thickeners.
- the medium- or short-chain triglycerides act as plasticizers.
- esters of fatty acid and sorbitan (marketed for example under the name Span® ) and the fatty acid esters of polyethoxylated sorbitan (marketed for example under the name Tween® ) can be used as additives which may be incorporated into the semisolid matrix for filling gelatin capsules.
- the galenic forms of the invention are more particularly intended to improve the absorption of active ingredients which are hydrophilic and/or ionizable in physiological media corresponding to at least one of the following definitions:
- the partition coefficient D is determined in a conventional manner using the "shake flask” technique.
- a known quantity of product is introduced into a container containing octanol and water in equal parts (100 ml of water; 100 ml of octanol; the quantity of active ingredient being about 10 -3 M).
- the mixture is stirred until the product reaches its equilibrium state between the two phases.
- the phases are then separated.
- the product may be assayed in both phases by various known methods adapted to the nature of the active ingredient (spectrometry, chromatographic techniques).
- acamprosate As a particularly preferred active ingredient, there may be mentioned acamprosate as well as its pharmacologically acceptable salts.
- the pharmacologically acceptable salts are those commonly used in the art.
- the alkali and alkaline-earth metal salts are examples.
- the quantity of active ingredient present in the galenic forms of the invention varies between 0.001 and 95% by weight, preferably between 0.01 and 90%, or better still between 0.1 and 90%.
- the ratio of the active ingredient(s) to the absorption-promoting agent is between 0.001 and 10, for example between 0.01 and 10.
- the galenic forms of the invention may be provided in a solid form of the tablet or gelatin capsule type.
- the ratio of the active ingredient(s) to the absorption-promoting agent is between 1 and 10.
- the ratio of the active ingredient(s) to the absorption-promoting agent is between 0.1 and 2.
- the tablets according to the invention may comprise, in combination with the absorption-promoting agent, one or more additional excipients so as to obtain mono- or polyphase tablets.
- additional excipients so as to obtain mono- or polyphase tablets.
- Persons skilled in the art will choose these excipients according to the desired final properties, the application envisaged or so as to overcome a disadvantage linked to the method of manufacturing the tablets.
- excipients exist especially among the following categories: diluents, binders, lubricants, antioxidants, colorants, sweeteners, flavourings and acidulants, wetting agents, hydrophilizing agents such as sorbitol and cyclodextrins, osmotic agents such as mannitol, pH regulators, stabilizing agents such as trehalose and mannitol, adsorbants, chelating and sequestering agents and gastro-resistant film-coating excipients of the type including cellulose acetyl phthalate and polymethacrylates.
- any one of the following diluents or a combination thereof may be chosen: calcium carbonate, calcium sulphate, sucrose, dextrates, dextrin, dextrose, dicalcium phosphate dihydrate, kaolin, magnesium carbonate, magnesium oxide, maltodextrin, cellulose, microcrystalline cellulose, sorbitol, starches, pregelatinized starch, talc, tricalcium phosphate and lactose.
- binders there may be mentioned: gum arabic, gum tragacanth, guar gum, alginic acid, sodium alginate, sodium carboxymethylcellulose, dextrin, gelatin, hydroxyethylcellulose, hydroxypropylcellulose, liquid glucose, magnesium and aluminium silicate, maltodextrin, povidone, pregelatinized starch, starch and zein.
- the lubricants are glidants (such as anhydrous colloidal silicate, magnesium trisilicate, magnesium silicate, cellulose, starch, talc or tricalcium phosphate) or alternatively antifriction agents (such as calcium stearate, hydrogenated vegetable oils, paraffin, magnesium stearate, polyethylene glycol, sodium benzoate, sodium lauryl sulphate, fumaric acid, stearic acid or zinc stearate and talc).
- glidants such as anhydrous colloidal silicate, magnesium trisilicate, magnesium silicate, cellulose, starch, talc or tricalcium phosphate
- antifriction agents such as calcium stearate, hydrogenated vegetable oils, paraffin, magnesium stearate, polyethylene glycol, sodium benzoate, sodium lauryl sulphate, fumaric acid, stearic acid or zinc stearate and talc).
- antioxidants persons skilled in the art can select any of the following compounds: ascorbic acid, ascorbyl palmitate, fumaric acid, propyl gallate, sodium ascorbate and sodium metabisulphite, alpha-tocopherol, malic acid, butylated hydroxytoluene (BHT) and butylated hydroxyanisol (BHA).
- Preferred wetting agents are:
- acidifiers of the type including citric acid, hydrochloric acid, lactic acid, tartaric acid, as well as alcalinizing agents of the type including monoethanolamine, diethanolamine and triethanolamine, potassium citrate, sodium bicarbonate, sodium citrate dihydrate.
- adsorbants examples include bentonite, anhydrous colloidal silica, kaolin, magnesium and aluminium silicate, microcrystalline cellulose and cellulose.
- citric acid monohydrate edetic acid, disodium phosphate, monosodium phosphate, potassium citrate, tartaric acid and sodium citrate dihydrate.
- the binder may represent from 0.5 to 25% by weight, or better still from 2 to 5% by weight of the tablet.
- the lubricants are preferably incorporated into this tablet in an amount of 0.01 to 10% by weight.
- the quantity of gastro-resistant film-coating excipients varies between 0.5 and 9% by weight of the tablet.
- These tablets may be bare, but are preferably film-coated.
- the film-coating envisaged will make it possible to avoid an unpleasant taste by bringing about masking of the taste. It may participate in modifying the release of the active ingredient and/or of the promoting agent.
- a gastro-resistant film-coating will make it possible to avoid any release in the stomach; a film-coating which is more hydrophobic and insensitive to pH variations will contribute more towards extending the kinetics of dissolution.
- the film-forming agent may be supplemented with:
- the tablets of the invention are conventionally prepared by a method including the steps of granulation followed by compression. More precisely, the method of manufacture which is the subject of the invention comprises the steps consisting in:
- Step (a) involves the granulation of powders of amorphous or crystallized particles. This granulation is carried out in a manner known per se and, for example, by a wet granulation method.
- the granulation method comprises five essential steps: (i) dry mixing of the various constituents, (ii) wetting, (iii) actual granulation, (iv) drying, and then (v) sizing.
- the dry mixing consists of mixing the pulverulent excipients entering into the composition of the granules.
- the wetting consists of adding to the pulverulent mixture the various constituents, a wetting liquid which may be water, or an aqueous or organic solution of binder or an alcohol. This is carried out in a mixer-kneader of the planetary, roller, projection or whirling type or a mixer-granulator of the rapid type.
- the appropriate wetting liquid is water or an alcohol or an aqueous or organic solution of binder, as generally recommended in the art.
- the absorption-promoting agent is used as wetting liquid for the granulation.
- the drying may be carried out in an oven, or in a fluidized air bed dryer, or by microwave.
- the sizing is carried out by passing over a screen with a mesh opening of between 0.5 and 1.5 mm, preferably between 0.8 and 1.5 mm.
- a preferred mesh opening value is 1.25 mm.
- the invention does not intend to be limited to the use of a wet granulation method.
- persons skilled in the art will also be able to use other existing granulation methods, such as the dry granulation method.
- step d The last step of compression (step d) on an alternating or rotary machine leads to the formation of the tablet.
- the galenic forms of the invention may be provided in the form of gelatin capsules or any other substitute material, which may be monolithic, mono- or polyphasic.
- the content of the gelatin capsule is a matrix of the semisolid type.
- the active ingredient may be present in dissolved form or alternatively in suspension.
- the said matrix comprises the absorption-promoting agent described above, the active ingredient and optionally one or more additional excipients chosen from those described below so as to give the preparation the desired properties or so as to overcome the disadvantages linked to the process of preparing the gelatin capsules.
- excipients which may be incorporated into the semisolid matrix in combination with the mixture of absorption-promoting agents are of the following categories.
- the thickening agents may be added to the mixture of promoting agents in an amount of 0.1 per 1 to 10 per 1.
- the ratio which exists between the mixture of promoting agents and the mixture of thickening agents determines directly, for the same active ingredient, the kinetics of dissolution of the latter.
- the monolithic gelatin capsules of the invention are conventionally prepared by a method including a phase of preparing a semisolid matrix followed by casting into a gelatin capsule.
- the semisolid matrix is prepared by dispersing, with stirring, the active ingredient in the mixture of the various excipients.
- the use of subsidiary heating. of the container of mixture may be necessary in order to maintain this mixture of excipients in a liquid or semi-pasty state until the phase of casting into a gelatin capsule.
- gelatin capsule form may be replaced by a soft gelatin capsule form or any other substitute material. All the information cited above for the gelatin capsule, both in terms of composition and preparation of the semisolid matrix, remain applicable in this case.
- the galenic forms of the invention may be provided in the form of microgranules which may be packaged in a unit dose such as a gelatin capsule, a cachet or a sachet, or even a vial.
- the microgranules are obtained by combining the active ingredient and the absorption-promoting agent with one or more excipients chosen from the following categories:
- microgranules may be bare, but are preferably film-coated.
- the film-coating envisaged will make it possible to avoid an unpleasant taste by bringing about masking of the taste. It may participate in modifying the release of the active ingredient and/or of the promoting agent.
- a gastro-resistant film-coating will make it possible to avoid any release in the stomach; a film-coating which is more hydrophobic and insensitive to pH variations will contribute more towards extending the kinetics of dissolution.
- the film-forming agent Depending on the role attributed to the film-coating, persons skilled in the art will be able to choose the film-forming agent from among the following categories: cellulose derivatives such as hydroxypropylmethylcellulose, ethyl cellulose, cellulose acetophthalate, cellulose acetopropionate, cellulose trimelliate, the polymers and copolymers of methacrylic acid and its derivatives.
- cellulose derivatives such as hydroxypropylmethylcellulose, ethyl cellulose, cellulose acetophthalate, cellulose acetopropionate, cellulose trimelliate
- the film-forming agent will be supplemented with:
- the rate of film-coating may vary from 2 to 25% of the weight of the bare microgranules, preferably from 4 to 20% and more preferably from 5 to 20%.
- micro-granules differing from each other by their active ingredient and/or absorption-promoting agent and/or excipient compositions, or to even combine bare and film-coated microgranules, making it possible to adjust the kinetics of release of the active ingredient.
- microgranules are conventionally prepared by a method including incorporation of the mixture of absorption-promoting agents with the pulverulent mixture of the other excipients and of the active ingredient(s) into a high-speed mixer, followed by nucleation, swelling and spheronization.
- the film-coating phase it is conventionally carried out by spraying a suspension of film-forming agent and additives over a mass of moving microgranules in a turbine or more advantageously in a fluidized air bed apparatus.
- microgranules or a mixture thereof are placed in gelatin capsules in conventional manner using a filling device.
- a filling device for the latter operation, the incorporation of additives such as glidants, lubricants or even diluents may prove necessary.
- additives such as glidants, lubricants or even diluents may prove necessary.
- Persons skilled in the art will be able to choose either of these compounds from among the excipients cited in the corresponding paragraphs above.
- microgranules may have a size of between 0.1 and 3 mm, preferably between 0.2 and 2 mm and more preferably between 0.3 and 1.5 mm.
- polymeric derivatives may also be envisaged for this purpose.
- polymeric substance there may be mentioned semisynthetic celluloses of high molecular weight, carbomers such as polyacrylic acids, polymers and copolymers of methacrylic acid and its derivatives.
- the active ingredient is calcium acamprosate (or calcium acetylhomotaurinate) designated ACA in the text which follows.
- Precirol® and Precirol ATO5® are glycerol palmitostearate marketed by the company Gattefosse.
- Compritol® is glycerol behenate marketed by the company Gattefosse.
- Methocel K15M® is hydroxypropylcellulose marketed by the company Colorcon.
- Eudragit RS 30D® is a copolymer of acrylic acid ester and methacrylic acid esters, containing a low content of ammonium groups available from the company Rohm.
- Gelatin capsule containing a semisolid matrix providing immediate release of the active ingredient containing a semisolid matrix providing immediate release of the active ingredient.
- the excipients are melted at a temperature greater than their melting point, their mixture is homogenized and then the active ingredient is incorporated.
- the mixture is cast into gelatin capsules of size 00 in a sufficient quantity.
- the dissolution profiles for the gelatin capsules manufactured in the preceding example were determined after assaying by high-performance liquid chromatography.
- the gelatin capsules to be tested are introduced into reactors which were each previously filled with one litre of distilled water, at 37°C, and provided with a temperature regulating system and an efficient stirring system.
- samples of the medium contained in the reactor are collected, filtered on a membrane of porosity 0.45 ⁇ m (Millex HA, in cellulose acetate) and analysed by high-performance liquid chromatography (HPLC) with detection by UV spectrophotometry.
- HPLC high-performance liquid chromatography
- the quantity q of active ingredient present in the sample is determined by comparison with the area of the peak obtained under the same conditions with a reference solution of known concentration. A simple calculation makes it possible to find the total quantity of active ingredient released into the reactor at the instant t.
- the dissolution profile of the gelatin capsule is obtained by plotting on a curve the calculated quantities of active ingredient (expressed in percentage of the nominal dose) as a function of time. (See Figure 1).
- Gelatin capsules containing a semisolid matrix providing immediate release of the active ingredient are provided.
- Gelatin capsules containing a semisolid matrix providing prolonged release of the active ingredient The table below gives the composition by weight of each of the gelatin capsules Composition Gelatin capsule 4.1 Gelatin capsule 4.2 ACA 54% 54% Gélucire 44/14® 32% 22.5% truthcirol ® 13% 22.5% Soya bean lecithin 1% 1% The procedure is the same as that of Example 1.
- Gelatin capsules containing a semisolid matrix providing prolonged release of the active ingredient are provided.
- the procedure is the same as that of Example 1.
- the dissolution profiles obtained for these gelatin capsules by applying the analytical method of Example 2 are given in Figure 2.
- Gelatin capsules containing a semisolid matrix providing prolonged immediate release of the active ingredient.
- Gelatin capsules were filled both with a matrix obtained according to Example 1 and a matrix obtained according to Example 4, gelatin capsule 4.5.
- the weight ratio of the matrix of Example 1 to the matrix of Example 4 is 1:2.
- Gelatin capsules filled with microgranules for immediate release of the active ingredient are Gelatin capsules filled with microgranules for immediate release of the active ingredient.
- the pulverulent active ingredient and the excipient are introduced into a mixer of the rapid type. After the phases of melting of the excipient and then nucleation followed by swelling of the granules, the latter are spheronized.
- Gelatin capsules filled with microgranules for immediate release of the active ingredient were used in the following proportions (by weight):
- Gelatin capsule filled with microgranules for the prolonged release of the active ingredient is
- Gelatin capsules filled with microgranules for the prolonged release of the active ingredient are Gelatin capsules filled with microgranules for the prolonged release of the active ingredient.
- Gelatin capsules filled with microgranules with high floatability Gelatin capsules filled with microgranules with high floatability.
- Gelatin capsules filled with microgranules for the prolonged release of the active ingredient are Gelatin capsules filled with microgranules for the prolonged release of the active ingredient.
- the manufacture can be separated into two stages:
- Example 7.3 The microgranules obtained in Example 7.3 were film-coated using the following suspension of film-forming agent,
- the film-coating operation is carried out in a fluidized air bed apparatus.
- Gelatin capsules filled with microgranules for the prolonged release of the active ingredient are Gelatin capsules filled with microgranules for the prolonged release of the active ingredient.
- the manufacture can be separated into two stages:
- Example 7.3 The microgranules obtained in Example 7.3 were film-coated using the following suspension of film-forming agent,
- Gelatin capsules filled with two types of microgranules for the immediate and prolonged release of the active ingredient are two types of microgranules for the immediate and prolonged release of the active ingredient.
- the gelatin capsules were prepared by filling with a mixture of bare microgranules (obtained in Example 7.3) and of the film-coated microgranules (obtained in Example 13.2).
- the weight ratio of the microgranules of Example 7.3 to the microgranules of Example 13.2 is 40:60.
- Tablets for the immediate and prolonged release of the active ingredient were used in the following proportions by weight: Composition Tablet 15.1 Tablet 15.2 Tablet 15.3 Tablet 15.4 ACA 50% 50% 50% 50% 50% Gélucire 44 /14® 10% 10% 10% 10% Compritol® 20% 20% 10% 10% 10% Microcrystalline cellulose 9% 14% 19% 24% Povidone 10% 5% 10% 5% Mg stearate 1% 1% 1% 1% 1%
- the active ingredient is introduced into a rapid mixer-granulator, the molten Gélucire is added with stirring.
- Compritol® povidone and microcrystalline cellulose are then added to this pulverulent mixture which is subjected to stirring.
- the wetting liquid, purified water, is then added until well-formed granules and agglomerates are obtained.
- the whole is then dried (oven or fluidized air bed) and sized on a screen with a mesh opening of 1.25 mm.
- the dry granule is introduced into a rapid mixer-granulator, and then magnesium stearate is added.
- the lubricated granule is compressed on a rotary machine equipped, for example, with oblong dies.
- composition Bare core 50% Gélucire 44/14® 10% Compritol® 10% Microcrystalline cellulose 19% Povidone 10% Mg stearate 1% Film-coating HPMC 64% PEG 4000 15% Talc 21%
- the method of manufacture comprises two stages.
- the preparation of the bare cores is carried out as in Example 15; it is followed by film-coating in a turbine by spraying a suspension.
- composition Bare core ACA 47.5% Gélucire 44/14® 9.5%
- Compritol® 9.5%
- Povidone 9.5%
- Talc 5%
- the method of manufacture comprises two stages.
- the preparation of the bare cores is carried out as in Example 15; it is followed by film-coating in a turbine by spraying a suspension.
- a solution of carbon 14-labelled acamprosate, of known concentration, is placed in the apical compartment of a Grass Sweetana-type diffusion chamber which comprises a second so-called basolateral compartment separated from the first by an insert supporting a monocellular confluent culture of human colon adenocarcinoma endothelium epithelial cells, Caco-2 line.
- Plasma samples were collected just before the administration, and then 0.5; 1; 2; 3; 4; 5; 6; 8 and 24 hours after the administration. Using these samples, plasma acamprosate was assayed by gas chromatography/mass spectrometry (GC/MS). The following pharmacokinetic parameters were then determined for each administered form:
- the gelatin capsule form containing semisolid matrix of Example 1 and the immediate-release gelatin capsule form filled with microgranules of Example 7.1 allow an increase of about 40% in the relative bioavailability of calcium acetylhomotaurinate.
- the relative bioavailability of calcium acetylhomotaurinate was determined after administration of various prolonged-release oral formulations, and in comparison with two reference formulations: gastroresistant tablets at 500 mg and a formulation in the form of immediate-release gelatin capsules (Example 1). Furthermore, comparison of the plasma levels at 6 and 24 hours was carried out for all the forms tested. Protocol: The study was carried out on 6 dogs of Beagle breed.
- Plasma samples were collected just before the administration, and then 0.5; 1; 2; 3; 4; 5; 6; 8 and 24 hours after the administration. Using these samples, plasma acamprosate was assayed according to an LC/MS method. The following pharmacokinetic parameters were then determined for each administered form:
- the mean pharmacokinetic parameters observed for each of the forms tested are presented in the table below: Mean pharmacokinetic parameters for acamprosate observed in Beagle dogs after single oral administration of various modified-release galenic forms versus an immediate form. Mean Cmax (ng/ml) Frel. (%) C(6h) C(24h) Reference 2: immediate-release gelatin capsule with semisolid matrix Example 1 20,868 100 3433 69 Gelatin capsule with microgranules Example 14 12,448 67 2448 32 Prolonged-release matrix tablet Example 15.3 20,753 99 3916 261 Prolonged-release gelatin capsule with semisolid matrix Example 4.1 19,175 111 4471 82 Prolonged-release gelatin capsule with semisolid matrix Example 4.2 9363 64 3470 99
- the matrix tablet form (Example 15.3) and the semisolid gelatin capsule form (Example 4.1) make it possible to maintain or even increase the relative bioavailability of acamprosate, and furthermore the levels observed respectively at 6 h and 24 h are greater than those observed for the reference gelatin capsule: Example 1.
- Blood samples were collected at the following times: 0 - 0.5 - 1 - 1.5 - 2 - 3 - 4 - 5 - 6 - 8 - 10 - 12 -14 - 16 - 24 - 36 - 48 and 72 hours.
- the samples were assayed according to a method by gas-liquid chromatography coupled to mass spectrometry with detection by mass fragmentometry.
- the formulation in the form of a gelatin capsule with semisolid matrix makes it possible to obtain a larger plasma peak which indicates potentiation of the absorption which thereby causes an increase in bioavailability by a factor of 2.74 relative to a formulation in the form of a conventional gastroresistant tablet.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Addiction (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04001294A EP1410791B1 (en) | 1998-02-23 | 1999-02-16 | Orally administrable galenic form comprising metformine and an absorption-promoting agent |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR9802143 | 1998-02-23 | ||
FR9802143A FR2775188B1 (fr) | 1998-02-23 | 1998-02-23 | Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption |
PCT/EP1999/000994 WO1999042086A1 (en) | 1998-02-23 | 1999-02-16 | Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04001294A Division EP1410791B1 (en) | 1998-02-23 | 1999-02-16 | Orally administrable galenic form comprising metformine and an absorption-promoting agent |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1056445A1 EP1056445A1 (en) | 2000-12-06 |
EP1056445B1 true EP1056445B1 (en) | 2004-06-02 |
Family
ID=9523244
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04001294A Expired - Lifetime EP1410791B1 (en) | 1998-02-23 | 1999-02-16 | Orally administrable galenic form comprising metformine and an absorption-promoting agent |
EP99913165A Expired - Lifetime EP1056445B1 (en) | 1998-02-23 | 1999-02-16 | Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP04001294A Expired - Lifetime EP1410791B1 (en) | 1998-02-23 | 1999-02-16 | Orally administrable galenic form comprising metformine and an absorption-promoting agent |
Country Status (28)
Country | Link |
---|---|
US (2) | US6426087B1 (da) |
EP (2) | EP1410791B1 (da) |
JP (1) | JP4828020B2 (da) |
KR (1) | KR100587181B1 (da) |
CN (1) | CN1182837C (da) |
AP (1) | AP2000001943A0 (da) |
AR (2) | AR018109A1 (da) |
AT (2) | ATE408399T1 (da) |
AU (1) | AU750785B2 (da) |
BR (1) | BR9908121A (da) |
CA (1) | CA2321267C (da) |
CZ (1) | CZ299366B6 (da) |
DE (2) | DE69917750T2 (da) |
DK (2) | DK1056445T3 (da) |
ES (2) | ES2222695T3 (da) |
FR (1) | FR2775188B1 (da) |
HK (1) | HK1035142A1 (da) |
HU (1) | HU226732B1 (da) |
ID (1) | ID26022A (da) |
NO (1) | NO20004190L (da) |
OA (1) | OA11454A (da) |
PL (2) | PL191415B1 (da) |
PT (2) | PT1056445E (da) |
RU (1) | RU2228201C2 (da) |
SI (2) | SI1410791T1 (da) |
SK (2) | SK286248B6 (da) |
WO (1) | WO1999042086A1 (da) |
ZA (1) | ZA991408B (da) |
Families Citing this family (67)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9925127D0 (en) * | 1999-10-22 | 1999-12-22 | Pharmacia & Upjohn Spa | Oral formulations for anti-tumor compounds |
FR2805462B1 (fr) * | 2000-02-24 | 2003-08-15 | Therabel Res | Nouvelle forme galenique orale a liberation prolongee de la molsidomine |
DE10026699A1 (de) | 2000-05-30 | 2001-12-06 | Basf Ag | Formulierung auf Heparin-, Glycosaminoglycan- oder Heparinoidbasis und Verwendung der Formulierung sowie der Formulierungsgrundlage |
US7183410B2 (en) * | 2001-08-02 | 2007-02-27 | Bidachem S.P.A. | Stable polymorph of flibanserin |
US20030060475A1 (en) * | 2001-08-10 | 2003-03-27 | Boehringer Ingelheim Pharma Kg | Method of using flibanserin for neuroprotection |
UA78974C2 (en) | 2001-10-20 | 2007-05-10 | Boehringer Ingelheim Pharma | Use of flibanserin for treating disorders of sexual desire |
US10675280B2 (en) | 2001-10-20 | 2020-06-09 | Sprout Pharmaceuticals, Inc. | Treating sexual desire disorders with flibanserin |
SE0200475D0 (sv) * | 2002-02-15 | 2002-02-15 | Ltp Lipid Technologies Provide | Oral farmaceutisk beredning |
CA2481313A1 (en) | 2002-04-12 | 2003-10-23 | Merck & Co., Inc. | Bicyclic amides |
US20040048877A1 (en) * | 2002-05-22 | 2004-03-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions containing flibanserin |
US10004729B2 (en) | 2002-07-05 | 2018-06-26 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
FR2845289B1 (fr) * | 2002-10-04 | 2004-12-03 | Ethypharm Sa | Spheroides, procede de preparation et compositions pharmaceutiques. |
WO2004032860A2 (en) | 2002-10-07 | 2004-04-22 | Chiron Corporation | Hiv vaccine formulations |
US20040151769A1 (en) * | 2002-12-31 | 2004-08-05 | Boehringer Ingelheim International Gmbh | Film coated tablet containing an extract of red vine leaves |
ITRM20030074A1 (it) * | 2003-02-21 | 2004-08-22 | Pharmacia Italia Spa | Formulazioni semisolide a rilascio immediato intese |
US20040241252A1 (en) * | 2003-05-29 | 2004-12-02 | Abney Christopher Charles | Pharmaceutical compositions for oral administration comprising lithium carbonate, processes of making the same, and methods of administering the same |
WO2005060942A1 (en) * | 2003-12-19 | 2005-07-07 | Aurobindo Pharma Ltd | Extended release pharmaceutical composition of metformin |
US20050239798A1 (en) * | 2004-04-22 | 2005-10-27 | Boehringer Ingelheim Pharmaceuticals, Inc. | Method for the treatment of premenstrual and other female sexual disorders |
RU2445095C2 (ru) * | 2004-04-22 | 2012-03-20 | Бёрингер Ингельхайм Интернациональ Гмбх | Новые фармацевтические композиции для лечения сексуальных расстройств |
WO2005123134A2 (en) * | 2004-05-14 | 2005-12-29 | Cadila Healthcare Limited | A controlled release delivery system for metformin |
WO2005123039A1 (en) | 2004-06-12 | 2005-12-29 | Collegium Pharmaceutical, Inc. | Abuse-deterrent drug formulations |
US20060024370A1 (en) * | 2004-07-29 | 2006-02-02 | Cephalon France | Modafinil oral lyophilizate |
US20060025420A1 (en) * | 2004-07-30 | 2006-02-02 | Boehringer Ingelheimn International GmbH | Pharmaceutical compositions for the treatment of female sexual disorders |
CA2576812A1 (en) * | 2004-09-03 | 2006-03-09 | Boehringer Ingelheim International Gmbh | Method for the treatment of attention deficit hyperactivity disorder |
EP1796621B2 (en) * | 2004-10-01 | 2014-04-09 | Firmenich Sa | Perfuming or flavouring microcapsules comprising an explosion suppressant |
US20060199805A1 (en) * | 2005-03-04 | 2006-09-07 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders |
WO2006096439A2 (en) * | 2005-03-04 | 2006-09-14 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases |
EP1858516A1 (en) * | 2005-03-04 | 2007-11-28 | Boehringer Ingelheim International GmbH | Pharmaceutical compositions for the treatment and/or prevention of depression |
UY29445A1 (es) * | 2005-03-30 | 2006-10-02 | Generex Pharm Inc | Composiciones para la transmisión transmucosa oral de la metformina |
EP1904182A2 (en) * | 2005-05-06 | 2008-04-02 | Boehringer Ingelheim International GmbH | Method for the treatment of drug abuse with flibanserin |
EP1888070A1 (en) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Method for the treatment of sexual dysfunctions due to medical conditions |
EP1888071A1 (en) * | 2005-05-19 | 2008-02-20 | Boehringer Ingelheim International GmbH | Method for the treatment of drug-induced sexual dysfunction |
ES2322777T3 (es) * | 2005-06-21 | 2009-06-26 | Merck Patent Gmbh | Preparacion farmaceutica solida que contienen (r)-(-)-2-(5-(4-fluorfenil)-3-piridilmetilaminometil)-cromano. |
EP1745788A1 (de) * | 2005-07-22 | 2007-01-24 | KTB Tumorforschungsgesellschaft mbH | Acylglycerophospholipide zur Behandlung von Krebs und Tumorkachexie |
US8227476B2 (en) | 2005-08-03 | 2012-07-24 | Sprout Pharmaceuticals, Inc. | Use of flibanserin in the treatment of obesity |
US7923449B2 (en) * | 2005-10-29 | 2011-04-12 | Boehringer Ingelheim International Gmbh | Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders |
US20070123540A1 (en) * | 2005-10-29 | 2007-05-31 | Angelo Ceci | Sexual desire enhancing medicaments comprising benzimidazolone derivatives |
US20070105869A1 (en) * | 2005-11-08 | 2007-05-10 | Stephane Pollentier | Use of flibanserin for the treatment of pre-menopausal sexual desire disorders |
WO2007106957A1 (en) * | 2006-03-21 | 2007-09-27 | Laboratoires Smb S.A. | Multiple units controlled-release floating dosage forms |
AU2007247094B2 (en) * | 2006-05-09 | 2012-11-01 | Sprout Pharmaceuticals, Inc. | Use of flibanserin for the treatment of post-menopausal Sexual Desire Disorders |
CA2654798C (en) | 2006-06-30 | 2015-01-13 | Boehringer Ingelheim International Gmbh | Flibanserin for the treatment of urinary incontinence and related diseases |
EP2043648A1 (en) * | 2006-07-14 | 2009-04-08 | Boehringer Ingelheim International GmbH | Use of flibanserin for the treatment of sexual disorders in females |
CL2007002214A1 (es) * | 2006-08-14 | 2008-03-07 | Boehringer Ingelheim Int | Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp |
AU2007286288A1 (en) * | 2006-08-14 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Formulations of flibanserin and method for manufacturing the same |
WO2008022932A2 (en) * | 2006-08-25 | 2008-02-28 | Boehringer Ingelheim International Gmbh | Controlled release system and method for manufacturing the same |
US20080081142A1 (en) * | 2006-10-03 | 2008-04-03 | Zeik Douglas B | Articles and methods for applying color on surfaces |
EP1952803A1 (en) * | 2007-01-23 | 2008-08-06 | KTB-Tumorforschungs GmbH | Solid pharmaceutical dosage form containing hydrogenated phospholipids |
US20090069419A1 (en) * | 2007-09-07 | 2009-03-12 | Bernd Jandeleit | Masked carboxylate neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
WO2009033079A1 (en) * | 2007-09-07 | 2009-03-12 | Xenoport, Inc. | Externally masked neopentyl sulfonyl ester cyclization release prodrugs of acamprosate, compositions thereof, and methods of use |
UY31335A1 (es) | 2007-09-12 | 2009-04-30 | Tratamiento de sintomas vasomotores | |
EP2042165A1 (de) * | 2007-09-28 | 2009-04-01 | Swiss Caps Rechte und Lizenzen AG | Hot-Melt-Befüllte Weichkapseln |
US20090099253A1 (en) * | 2007-10-15 | 2009-04-16 | Xenoport, Inc. | Internally Masked Neopentyl Sulfonyl Ester Cyclization Release Prodrugs of Acamprosate, Compositions Thereof, and Methods of Use |
CA2638240C (en) * | 2008-08-29 | 2010-02-02 | Alexander Macgregor | Method of treating dysglycemia and glucose excursions |
JP2012509921A (ja) | 2008-11-27 | 2012-04-26 | ビーエーエスエフ ソシエタス・ヨーロピア | 固形製薬学的処方物中への付形剤としての表面活性タンパク質 |
US10668060B2 (en) | 2009-12-10 | 2020-06-02 | Collegium Pharmaceutical, Inc. | Tamper-resistant pharmaceutical compositions of opioids and other drugs |
DK2512455T3 (da) | 2009-12-18 | 2014-03-24 | Frieslandcampina Nederland Holding B V | Sambehandlet tablethjælpestofsammensætning, dens fremstilling og anvendelse |
JP5546900B2 (ja) * | 2010-02-25 | 2014-07-09 | ライオン株式会社 | パナキサトリオール安定化組成物 |
US9000046B2 (en) * | 2010-09-28 | 2015-04-07 | Depomed, Inc. | Gastric retentive dosage forms for extended release of acamprosate into the upper gastrointestinal tract |
RU2671399C2 (ru) * | 2011-12-02 | 2018-10-31 | Синкроньюэрон Инк. | Композиции акампросата, способы их применения и содержащие их комбинации |
US20130143867A1 (en) | 2011-12-02 | 2013-06-06 | Sychroneuron Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US20150246060A1 (en) | 2013-03-15 | 2015-09-03 | Iceutica Inc. | Abiraterone Acetate Formulation and Methods of Use |
MX2015013247A (es) * | 2013-03-15 | 2016-11-25 | Iceutica Inc | Formulacion de acetato de abiraterona. |
WO2014197744A1 (en) | 2013-06-05 | 2014-12-11 | Synchroneuron, Inc. | Acamprosate formulations, methods of using the same, and combinations comprising the same |
US20150157646A1 (en) | 2013-09-27 | 2015-06-11 | Iceutica Inc. | Abiraterone Steroid Formulation |
WO2017222575A1 (en) | 2016-06-23 | 2017-12-28 | Collegium Pharmaceutical, Inc. | Process of making more stable abuse-deterrent oral formulations |
EP3624788A4 (en) * | 2017-05-17 | 2021-03-03 | Confluence Pharmaceuticals, LLC | FORMULATIONS OF HOMOTAURINS AND THEIR SALTS |
WO2023025672A1 (en) | 2021-08-25 | 2023-03-02 | Basf Se | Direct tableting auxiliary composition |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI63335B (fi) * | 1979-02-02 | 1983-02-28 | Orion Yhtymae Oy | Foerfarande foer framstaellning av tabletter med foerdroejd loslighet av effektaemne |
FR2457281A1 (fr) * | 1979-05-23 | 1980-12-19 | Meram Lab | Nouveaux derives de l'acide 3-aminopropanesulfonique ayant une activite membranaire renforcee |
GB8524421D0 (en) * | 1985-10-03 | 1985-11-06 | Boots Co Plc | Therapeutic agents |
JPS62265226A (ja) * | 1986-05-12 | 1987-11-18 | Fujisawa Pharmaceut Co Ltd | 経口投与用製剤 |
ZA898331B (en) * | 1988-11-22 | 1990-07-25 | Hoffmann La Roche | Pharmaceutical compositions |
US5190748A (en) * | 1988-11-22 | 1993-03-02 | Hoffmann-La Roche Inc. | Absorption enhancement of antibiotics |
US5139786A (en) * | 1989-07-07 | 1992-08-18 | Ciba-Geigy Corporation | Topical formulations |
JPH03275633A (ja) * | 1990-03-23 | 1991-12-06 | Teikoku Seiyaku Co Ltd | 生理活性ポリペプチドの吸収促進剤 |
US5138786A (en) | 1991-07-17 | 1992-08-18 | Fischer Michael G | Insta-guard firearm protection |
IT1255895B (it) * | 1992-10-20 | 1995-11-17 | Laura Chiodini | Composizioni farmaceutiche contenenti una calcitonina |
DE4432757A1 (de) * | 1994-09-14 | 1996-03-21 | Boehringer Mannheim Gmbh | Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung |
US5858398A (en) * | 1994-11-03 | 1999-01-12 | Isomed Inc. | Microparticular pharmaceutical compositions |
GB9516268D0 (en) * | 1995-08-08 | 1995-10-11 | Danbiosyst Uk | Compositiion for enhanced uptake of polar drugs from the colon |
-
1998
- 1998-02-23 FR FR9802143A patent/FR2775188B1/fr not_active Expired - Fee Related
-
1999
- 1999-02-16 HU HU0100970A patent/HU226732B1/hu not_active IP Right Cessation
- 1999-02-16 AP APAP/P/2000/001943A patent/AP2000001943A0/en unknown
- 1999-02-16 DE DE69917750T patent/DE69917750T2/de not_active Expired - Lifetime
- 1999-02-16 DE DE69939605T patent/DE69939605D1/de not_active Expired - Lifetime
- 1999-02-16 PT PT99913165T patent/PT1056445E/pt unknown
- 1999-02-16 KR KR1020007009307A patent/KR100587181B1/ko not_active IP Right Cessation
- 1999-02-16 CA CA002321267A patent/CA2321267C/en not_active Expired - Fee Related
- 1999-02-16 CZ CZ20002940A patent/CZ299366B6/cs not_active IP Right Cessation
- 1999-02-16 PL PL342162A patent/PL191415B1/pl unknown
- 1999-02-16 AT AT04001294T patent/ATE408399T1/de active
- 1999-02-16 SK SK5107-2005A patent/SK286248B6/sk not_active IP Right Cessation
- 1999-02-16 ES ES99913165T patent/ES2222695T3/es not_active Expired - Lifetime
- 1999-02-16 PL PL377398A patent/PL201851B1/pl unknown
- 1999-02-16 AU AU31408/99A patent/AU750785B2/en not_active Ceased
- 1999-02-16 EP EP04001294A patent/EP1410791B1/en not_active Expired - Lifetime
- 1999-02-16 WO PCT/EP1999/000994 patent/WO1999042086A1/en active IP Right Grant
- 1999-02-16 AT AT99913165T patent/ATE268164T1/de active
- 1999-02-16 CN CNB998032182A patent/CN1182837C/zh not_active Expired - Fee Related
- 1999-02-16 SK SK1255-2000A patent/SK285188B6/sk not_active IP Right Cessation
- 1999-02-16 RU RU2000124535/15A patent/RU2228201C2/ru not_active IP Right Cessation
- 1999-02-16 PT PT04001294T patent/PT1410791E/pt unknown
- 1999-02-16 ID IDW20001870A patent/ID26022A/id unknown
- 1999-02-16 BR BR9908121-0A patent/BR9908121A/pt not_active Application Discontinuation
- 1999-02-16 JP JP2000532103A patent/JP4828020B2/ja not_active Expired - Fee Related
- 1999-02-16 DK DK99913165T patent/DK1056445T3/da active
- 1999-02-16 ES ES04001294T patent/ES2314302T3/es not_active Expired - Lifetime
- 1999-02-16 EP EP99913165A patent/EP1056445B1/en not_active Expired - Lifetime
- 1999-02-16 SI SI9931019T patent/SI1410791T1/sl unknown
- 1999-02-16 DK DK04001294T patent/DK1410791T3/da active
- 1999-02-16 SI SI9930637T patent/SI1056445T1/xx unknown
- 1999-02-16 US US09/622,663 patent/US6426087B1/en not_active Expired - Lifetime
- 1999-02-22 ZA ZA9901408A patent/ZA991408B/xx unknown
- 1999-02-23 AR ARP990100731A patent/AR018109A1/es active IP Right Grant
-
2000
- 2000-08-22 NO NO20004190A patent/NO20004190L/no not_active Application Discontinuation
- 2000-08-22 OA OA1200000231A patent/OA11454A/en unknown
-
2001
- 2001-08-17 HK HK01105794A patent/HK1035142A1/xx not_active IP Right Cessation
-
2002
- 2002-03-19 US US10/100,084 patent/US6514524B1/en not_active Expired - Lifetime
-
2008
- 2008-06-04 AR ARP080102354A patent/AR066843A2/es active IP Right Grant
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1056445B1 (en) | Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent | |
EP1062952B1 (en) | Bubbling enteric preparations | |
KR100203339B1 (ko) | 의약용 방출조절 매트릭스 | |
US6491950B1 (en) | Controlled release pharmaceutical composition | |
CN103228277A (zh) | 难溶性药物的溶解性改善制剂 | |
JP2007532532A (ja) | HMG−CoA還元酵素阻害剤の経口投与用徐放性製剤およびその製造方法 | |
JP2008534584A (ja) | フェノフィブラート含有メントール又はpeg/ポロキサマー混合物の改良製剤 | |
US20040115264A1 (en) | Fenofibrate tablets | |
US9682148B2 (en) | Solid oral dosage form of testosterone derivative | |
US20110217369A1 (en) | Fenofibrate compositions | |
MXPA00008203A (en) | Orally administrable immediate-release and prolonged-release galenic form comprising an absorption-promoting agent and use of this absorption-promoting agent | |
CA2531097C (en) | Process for preparing formulations of lipid-regulating drugs | |
KR20210024566A (ko) | 유지 중에 ed-71 및 그의 에폭시체를 포함하는 유분 분산체를 포함하는 의약 조성물 | |
EP1408934A2 (en) | Pharmaceutical composition for prophylaxis and treatment of calcium metabolism disorders comprising clodronate in combination with glyceryl palmitostearate |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20000630 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Free format text: LT PAYMENT 20000630;LV PAYMENT 20000630;RO PAYMENT 20000630;SI PAYMENT 20000630 |
|
17Q | First examination report despatched |
Effective date: 20020611 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61K 31/16 B Ipc: 7A 61K 47/26 B Ipc: 7A 61K 47/14 B Ipc: 7A 61K 9/48 B Ipc: 7A 61K 9/20 B Ipc: 7A 61K 9/16 A |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU NL PT SE |
|
AX | Request for extension of the european patent |
Extension state: LT LV RO SI |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REF | Corresponds to: |
Ref document number: 69917750 Country of ref document: DE Date of ref document: 20040708 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: NV Representative=s name: BOVARD AG PATENTANWAELTE |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: EP Ref document number: 20040402604 Country of ref document: GR |
|
REG | Reference to a national code |
Ref country code: PT Ref legal event code: SC4A Free format text: AVAILABILITY OF NATIONAL TRANSLATION Effective date: 20040831 |
|
REG | Reference to a national code |
Ref country code: SI Ref legal event code: IF |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2222695 Country of ref document: ES Kind code of ref document: T3 |
|
ET | Fr: translation filed | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20050216 |
|
ET1 | Fr: translation filed ** revision of the translation of the patent or the claims | ||
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20050303 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PFA Owner name: MERCK PATENT GMBH Free format text: MERCK PATENT GMBH#FRANKFURTER STRASSE 250#64293 DARMSTADT (DE) -TRANSFER TO- MERCK PATENT GMBH#FRANKFURTER STRASSE 250#64293 DARMSTADT (DE) |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: PLFP Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20150110 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: CH Payment date: 20150213 Year of fee payment: 17 Ref country code: PT Payment date: 20150216 Year of fee payment: 17 Ref country code: FI Payment date: 20150209 Year of fee payment: 17 Ref country code: LU Payment date: 20150204 Year of fee payment: 17 Ref country code: IE Payment date: 20150210 Year of fee payment: 17 Ref country code: DK Payment date: 20150210 Year of fee payment: 17 Ref country code: IT Payment date: 20150218 Year of fee payment: 17 Ref country code: ES Payment date: 20150113 Year of fee payment: 17 Ref country code: DE Payment date: 20150210 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20150212 Year of fee payment: 17 Ref country code: AT Payment date: 20150126 Year of fee payment: 17 Ref country code: GB Payment date: 20150211 Year of fee payment: 17 Ref country code: FR Payment date: 20150210 Year of fee payment: 17 Ref country code: GR Payment date: 20150114 Year of fee payment: 17 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: BE Payment date: 20150211 Year of fee payment: 17 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160229 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 69917750 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: LT Ref legal event code: MM9D Effective date: 20160216 |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: EBP Effective date: 20160229 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: EUG |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MM01 Ref document number: 268164 Country of ref document: AT Kind code of ref document: T Effective date: 20160216 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20160216 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160229 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160229 Ref country code: FI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: MM Effective date: 20160301 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20161028 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 Ref country code: SE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160217 Ref country code: GR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160905 Ref country code: PT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160816 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: MM4A Ref country code: SI Ref legal event code: KO00 Effective date: 20161013 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160229 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160216 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160901 Ref country code: NL Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160301 Ref country code: DK Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160229 |
|
REG | Reference to a national code |
Ref country code: GR Ref legal event code: ML Ref document number: 20040402604 Country of ref document: GR Effective date: 20160905 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20160217 |